How should I taper off Lamictal (lamotrigine)?

Mood stabilizer with critical re-titration requirement: if therapy is interrupted >5 days, restart from low dose with full titration to mitigate SJS/TEN risk. Chewable/dispersible tablets (2, 5, 25 mg) support fine dose adjustments. Monitor for breakthrough seizures and bipolar relapse during taper. Gradual taper essential. If dosing is interrupted >5 days, re-titrate from baseline due to serious rash risk on rapid re-introduction. Chewable/dispersible tablets (2, 5, 25 mg) enable proportional reductions. Co-medication with valproate or enzyme inducers materially affects clearance — adjust accordingly.

Lamictal Tapering Guide

Q: What are the withdrawal symptoms of Lamictal (lamotrigine)?

Common withdrawal symptoms of Lamictal (lamotrigine) include: seizure risk, mood instability, anxiety, insomnia, irritability. Symptom severity varies by individual, dose, and duration of use.

lamotrigine

OtherFDA 1994

Try TaperMeds

Boxed Warning

Serious skin rashes including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), especially during initial titration. Increased risk of suicidal thoughts and behavior (anticonvulsant class warning).

Overview

Lamotrigine is an anticonvulsant approved for epilepsy (partial seizures, primary generalized tonic-clonic seizures, Lennox-Gastaut syndrome) and maintenance treatment of bipolar I disorder. It is the only mood stabilizer with strong evidence for preventing bipolar depression.

Common Doses

25mg, 50mg, 100mg, 200mg

Formulations

Tablets: 25mg, 100mg, 150mg, 200mg; Chewable/dispersible tablets: 2mg, 5mg, 25mg; Orally disintegrating tablets (ODT): 25mg, 50mg, 100mg, 200mg; Extended-release tablets (XR): 25mg, 50mg, 100mg, 200mg, 250mg, 300mg

Pregnancy

Category C (risk cannot be ruled out)

Mechanism of Action

Blocks voltage-sensitive sodium channels, stabilizing neuronal membranes and inhibiting release of excitatory neurotransmitters (primarily glutamate). May also modulate calcium channels and HCN channels. The anti-glutamate mechanism is thought to underlie its mood-stabilizing effects.

Taper Notes

Mood stabilizer with critical re-titration requirement: if therapy is interrupted >5 days, restart from low dose with full titration to mitigate SJS/TEN risk. Chewable/dispersible tablets (2, 5, 25 mg) support fine dose adjustments. Monitor for breakthrough seizures and bipolar relapse during taper.

Maudsley Deprescribing Guidance

Gradual taper essential. If dosing is interrupted >5 days, re-titrate from baseline due to serious rash risk on rapid re-introduction. Chewable/dispersible tablets (2, 5, 25 mg) enable proportional reductions. Co-medication with valproate or enzyme inducers materially affects clearance — adjust accordingly.

Common Withdrawal Symptoms

seizure riskmood instabilityanxietyinsomniairritability

Interactions & Safety

Drug Interactions

Valproate significantly increases lamotrigine levels (~2x) by inhibiting glucuronidation — must halve lamotrigine dose
Enzyme inducers (carbamazepine, phenytoin, phenobarbital, primidone, rifampin) decrease lamotrigine levels — dose adjustment needed
Oral contraceptives (estrogen-containing) decrease lamotrigine levels by ~50% — dose adjustment needed during pill-free week

Food Interactions

Food does not affect absorption
No significant food interactions

Contraindications

Known hypersensitivity to lamotrigine

Toxicity

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) — risk highest with rapid titration, concurrent valproate, and in children. Aseptic meningitis. Multiorgan hypersensitivity (DRESS). Suicidal ideation (anticonvulsant class warning).

Pharmacokinetics

ADME Profile

Absorption

Rapidly and completely absorbed after oral administration. Bioavailability ~98%. Tmax ~1.4–4.8 hours. Food does not affect absorption.

Distribution

~0.9–1.3 L/kg

Metabolism

Hepatic via UGT glucuronidation (primarily UGT1A4). Does not undergo significant CYP metabolism. Valproate inhibits lamotrigine glucuronidation (doubles half-life); enzyme inducers (carbamazepine, phenytoin) accelerate metabolism.

Elimination

Renal (~94%, with ~10% as unchanged lamotrigine and ~76% as 2-N-glucuronide conjugate). Fecal (~2%).

Protein Binding

~55%

Clearance

~30 mL/min (apparent clearance; varies significantly with co-medications)

Build Lamictal taper plans in minutes

TaperMeds turns these protocols into prescriber-ready taper schedules with hyperbolic dose curves, symptom tracking, and patient handouts — for the clinicians supervising the taper.